Navigation Links
SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
Date:6/16/2011

are convertible.  The exercise price of such warrant is $0.0625 per share.

The Debentures were offered in the private placement pursuant to Regulation D under the Securities Act of 1933, as amended (the "Securities Act").  Neither the Debentures, nor the underlying common stock into which the Debentures are convertible, have been registered under the Securities Act, and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements. This press release does not and will not constitute an offer to sell or the solicitation of an offer to buy Debentures or any other security of the Company, and is being issued pursuant to the safe-harbor provisions of Rule 135c under the Securities Act.

FORWARD-LOOKING STATEMENTS — The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements (statements other than statements of historical fact).  Forward-looking statements may generally be identified by the inclusion of the words "may," "will," "would," "could," "believes," "expects," "anticipates," "intends," "plans," "projects," "considers" and similar expressions).  This news release contains forward-looking statements, including information regarding a private securities offering conducted by SCOLR Pharma, Inc., and the use of proceeds therefrom. These forward-looking statements are based on certain assumptions and expectations of SCOLR Pharma, Inc., and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks and uncertainties referenced from time to time in SCOLR Pharma, Inc.'s filings with the Securities and Exchange Commission.  Readers are cautioned not to place undue reliance on such forward-looking
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
6. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
7. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
8. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
9. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... from finely etched lines in silicon wafers to ... of Energy,s Lawrence Berkeley National Laboratory (Berkeley Lab) ... through a molecular junctiona nanometer scale circuit element ... Their findings reveal the electrical resistance through this ...
... ONTY ) (TSX:ONY), a biotechnology company specializing ... treatment of cancer, today announced that it intends to ... results on Monday, March 9, 2009 after the close ... Oncothyreon,s management expects to discuss these financial results and ...
... an unknown organism often calls for total shutdown ... be identified and eliminated. Such shutdowns can ... of medical device and pharmaceutical manufacturers alike.A new ... DNA Sequencing Services Help Prevent Catastrophic Cleanroom Shutdowns ...
Cached Biology Technology:Researchers discover a potential on-off switch for nanoelectronics 2Researchers discover a potential on-off switch for nanoelectronics 3Researchers discover a potential on-off switch for nanoelectronics 4White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 2White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 3
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... team led by two Texas A&M University anthropologists now ... to 2,000 years earlier than the 13,500 years ago ... The teams findings are outlined in a review article ... Modern Humans in the Americas, which synthesizes new data ...
... solar cells can be found in dye-sensitised solar cells. This ... energy by, for instance, plants and light-sensitive bacteria. Annemarie Huijser ... of solar cell, which is similar to Grtzel cells. Huijser ... on Tuesday 25 March. The use of solar cells ...
... . , OTTAWA The Government of ... of chemicals that can be used to make explosives. ... the Honourable Stockwell Day, Minister of Public Safety, today ... explosives precursors, will be implemented under the Explosives Act. ...
Cached Biology News:Substantial improvement in essential cheap solar cell process 2New regulations tighten controls on restricted chemicals 2
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... DNase I Amplification Grade ... DNA to oligodeoxyribonucleotides. The ... units/mg. DNAse I Amplification ... and tested for absence ...
... of Cell Cultures (ECACC) in conjunction with ... West of England, Bristol, UK, have produced ... of HER2, oestrogen and progresterone receptor assays. ... of formalin fixed, breast cancer cell lines; ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
Biology Products: